Immune response in non-small cell lung cancer treated with durvalumab after chemoradiotherapy
Looks at immune response in adults with inoperable non-small cell lung cancer receiving durvalumab.
Plain-language title generated from the registry record
Registry title: Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Key facts
- Where
- A Coruña, Alicante, Badalona, Barcelona, Bilbao, Ciudad Real, Ferrol, Girona, Las Palmas de Gran Canaria, Lugo, Madrid, Majadahonda, Oviedo, Santa Cruz de Tenerife, Seville, Valencia, Valladolid, and Vigo, SpainSee the 22 sites
Where in Spain
- Hospitalario Universitario A CoruñaA Coruña, SpainTaking people
- Hospital General Universitario de AlicanteAlicante, SpainTaking people
- ICO Badalona, Hospital Germans Trias i PujolBadalona, SpainTaking people
- Hospital de la Santa Creu i Sant PauBarcelona, SpainTaking people
- Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
- Hospital De BasurtoBilbao, SpainTaking people
- Hospital General Universitario de Ciudad RealCiudad Real, SpainTaking people
- Complejo Hospitalario Universitario Del FerrolFerrol, SpainTaking people
- ICO Girona, Hospital Josep TruetaGirona, SpainTaking people
- Hospital Universitari de Gran Canària Doctor NegrínLas Palmas de Gran Canaria, SpainTaking people
- Hospital Universitario Lucus AugustiLugo, SpainTaking people
- Hospital Clínico San CarlosMadrid, SpainTaking people
- Hospital Universitario de la PrincesaMadrid, SpainTaking people
- Hospital Universitario Fundación Jiménez DíazMadrid, SpainTaking people
- Hospital Universitario La PazMadrid, SpainTaking people
- Hospital Universitario Puerta de HierroMajadahonda, SpainTaking people
- Hospital Universitario Central De AsturiasOviedo, SpainTaking people
- Hospital Universitario Nuestra Señora de CandelariaSanta Cruz de Tenerife, SpainTaking people
- Hospital Virgen Del RocioSeville, SpainTaking people
- Hospital Universitario Y Politecnico La FeValencia, SpainTaking people
- Hospital Clínico Universitario de ValladolidValladolid, SpainTaking people
- Complexo Hospitalario Universitario De VigoVigo, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundación GECP
- Trial code
- NCT06634199
- Record updated
- 28 January 2026
- Original description
Observational, multicenter, one-arm, non-comparative study. Data will be recorded in a retrospectively manner. The study will be based on secondary data collected from patient clinical chart completed by the doctor during routine visits. The primary objective is describe the antitumor immune response generated in the context of IO (immunotherapy) treatment after cCRT in patients with unresectable NSCLC treated in real world.Read full original descriptionShow less
Study of Antitumor Immune Response Generated After Concurrent Chemo-radiotherapy (cCRT) and IO Treatment in Non-resectable Stage IIIA/B and IIIC NSCLC Patients Treated in Real World.
Observational, multicenter, one-arm, non-comparative study. Data will be recorded in a retrospectively manner. The study will be based on secondary data collected from patient clinical chart completed by the doctor during routine visits. The primary objective is describe the antitumor immune response generated in the context of IO (immunotherapy) treatment after cCRT in patients with unresectable NSCLC treated in real world.
Inclusion: Patients with histologically- or cytologically- documented NSCLC who present unresectable stage IIIA-IIIB-IIIC disease, according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology); ECOG 0-1; PDL1>1%; Age ≥ 18 years at time of study; Patients without progression after cCRT, that are going to receive IO treatment (Durvalumab) for 12 months as subsequent treatment as per standard clinical practice; Patient capable of proper therapeutic compliance and accessible for correct follow-up; Patients must have signed, dated and IRB/EC-approved written informed consent form in accordance with regulatory and institutional guidelines.
Exclusion: Any medical, mental, or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information; Patients who refuse to sign and date an IRB/IEC-approved written informed consent form; No possibility of venipuncture.